Amneal Launches US Rival To Butrans
Receives 180 Days Of Competitive Generic Therapy Exclusivity
Following approval by the FDA, Amneal has launched a generic version of the Butrans buprenorphine transdermal system, immediately initiating commercialization activities across all strengths.
